Journal article
Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: Outcomes and treatment effect across different levels of risk
Abstract
BACKGROUND: The OASIS-5 (Organization to Assess Strategies in Ischemic Syndromes-5) trial demonstrated that fondaparinux was noninferior to enoxaparin while reducing the risk of bleeding by 50%. The objectives of our study were to assess the effects of fondaparinux compared to enoxaparin in patients stratified by their Global Registry of Acute Coronary Events (GRACE) score and to examine the ability of the GRACE score to predict bleeding in …
Authors
Joyner CD; Peters RJG; Afzal R; Chrolavicius S; Mehta SR; Fox KAA; Granger CB; Franzosi MG; Flather M; Budaj A
Journal
American Heart Journal, Vol. 157, No. 3, pp. 502–508
Publisher
Elsevier
Publication Date
3 2009
DOI
10.1016/j.ahj.2008.10.028
ISSN
0002-8703